The purchase data analytics platform, which is backed by Aimia and Fidelity Information Services, had raised almost $210m in venture financing.

The Xiaomi-affiliated smart wearable device maker has become the latest Chinese company to go public in the US, floating in the middle of its range.

Novo and Lundbeck-backed Acacia Pharma previously withdrew plans for a $230m initial public offering on the London Stock Exchange in 2015.

The respiratory tract infection therapy developer, which counts Novartis and PureTech Health as investors, has closed its IPO at $97.8m.

The pruritus treatment developer, which counts Novo and Merck & Co as shareholders, has closed its initial public offering, its shares having almost doubled in price.

The immuno-oncology drug developer, which is backed by Celgene and GV, floated above its range and has since seen its share price rise 75%.

The seed and fertliliser producer, which counts Monsanto as an investor, has set the range for an initial public offering that could net up to $142m.

The Biogen-backed Duchenne muscular dystrophy drug developer saw its share price rise sharply after securing approximately $125m in its IPO.